Publications, Pharmaceutical

Delivering On The Promises of Intranasal Vaccination

Intranasal vaccination offers a number of valuable benefits. Nasal vaccines are easy to self-administer, non-invasive and trigger a broad immune response, notably mucosal immunity. This article reviews the advantages of intranasal vaccination, the challenges associated with developing nasal spray vaccines and recent advances in the field. COVID-19 has had a hugely disruptive impact on the vaccines market. Although only four nasal spray vaccines are currently in commercial use a significant number of intranasal spray vaccines for COVID-19 are in development, holding out the promise of adding mucosal immunity to improve resistance to the virus. The design of the drug delivery technology and emerging strategies for successful vaccine formulation are discussed.

For more information on ONdrugDelivery.

Download Publication
Author(s): Dr. Julie Suman Nektaria Karavas
18 Nov 2021

This Might Also Be of Interest

18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Apr 2018

A track record of success for nasal drug delivery in drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2016

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 24 25 26 27
Back To Top